BMC Medicine

CORRECTION

Correction: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)

Taku Kinoshita[1,2], Masahiro Shinoda[3], Yasuhiro Nishizaki[4], Katsuya Shiraki[5], Yuji Hirai[6], Yoshiko Kichikawa[7], Kenji Tsushima[1], Masaharu Shinkai[3], Naoyuki Komura[8], Kazuo Yoshida[9], Yasutoshi Kido[10,11,12], Hiroshi Kakeya[13,14], Naoto Uemura[15]* and Junichi Kadota[16,17]

Correction: BMC Med 20, 342 (2022)
https://doi.org/10.1186/s12916-022-02518-7

The original article [1] contained a small typo in Masaharu Shinkai's name which has since been corrected.

Author details

[1]Department of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, Narita, Japan. [2]Present Address: Respiratory Medicine, Chiba Rosai Hospital, Chiba, Japan. [3]Department of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan. [4]Tokai University Tokyo Hospital, Tokyo, Japan. [5]Department of General and Laboratory Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan. [6]Department of Infectious Diseases, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan. [7]Department of Respiratory Medicine, Mishuku Hospital, Tokyo, Japan. [8]Clinical Development Planning, Ono Pharmaceutical Co., Ltd., Osaka, Japan. [9]Department of Statistical Analysis, Ono Pharmaceutical Co., Ltd., Osaka, Japan. [10]Department of Parasitology and Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University, Osaka, Japan. [11]Department of Virology and Parasitology, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. [12]Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. [13]Department of Infection Control Science, Graduate School of Medicine, Osaka City University, Osaka, Japan. [14]Department of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan. [15]Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita-ken 879-5593, Japan. [16]Department of Respiratory Medicine and Infectious Diseases, Faculty of Medicine, Oita University, Oita, Japan. [17]Nagasaki Harbor Medical Center, Nagasaki, Japan.

Reference

1. Kinoshita T, et al. A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study). BMC Med. 2022;20:342. https://doi.org/10.1186/s12916-022-02518-7.

*Correspondence: uemura@oita-u.ac.jp

[15] Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita-ken 879-5593, Japan
Full list of author information is available at the end of the article